Atai
Atai Life Sciences NV (ATAI) clinical-stage biopharmaceutical firm seeking to revolutionize the way we treat mental health disorders. The company has spent years developing psychedelic therapies based on substances such as psychedelic substances like Psilocybin, R-ketamine, Ibogaine, DMT, and MDMA derivatives.
Not only is Atai the largest player in this market, valued at over $265 million but it’s also backed by prominent tech figures such as Peter Thiel. The company is also one of the few to have a partnership with a major pharmaceutical company. It’s working with Japanese drugmaker Otsuka to develop a depression treatment based on r-ketamine.
The stock has dropped 90% since its listing in 2021, which highlights how precarious this industry is.
Invest in real estate without the headache of being a landlord
Imagine owning a portfolio of thousands of well-managed single family rentals or a collection of cutting-edge industrial warehouses. You can now gain access to a $1B portfolio of income-producing real estate assets designed to deliver long-term growth from the comforts of your couch.
The best part? You don’t have to be a millionaire and can start investing in minutes.
Learn MoreCompass
Initially launched as a not-for-profit in 2015 to research the use of psychedelic drugs on anxiety and depression, Compass Pathways pivoted to for-profit in 2016 and listed on the NASDAQ in 2020.
Since then, the stock has lost 72% of its market value. However, its drug development pipeline is still moving forward. Compass successfully completed its phase 2 study evaluating COMP360 in treatment-resistant depression. This was the largest clinical trial in the history of psilocybin therapy. Now the company is working on similar studies focused on post-traumatic stress disorder (PTSD) treatments.
Some of Compass’ research and development is funded by Atai, which owns a minority stake in the firm. This base of investors and success at clinical trials makes Compass an interesting opportunity for investors.
CYBIN
Toronto-based Cybin has completed over 140 preclinical trials of its various psychedelic treatments for mental health disorders. One of its leading candidates is a drug labeled CYB001, which is designed to potentially treat major depressive disorder.
Cybin stock is down 75% over the past year, which means its market value is smaller than its rivals mentioned above. Investors should consider this a penny stock in the risky world of psychedelics.
Sponsored
Follow These Steps if you Want to Retire Early
Secure your financial future with a tailored plan to maximize investments, navigate taxes, and retire comfortably.
Advisor is an online platform that can match you with a network of vetted fiduciary advisors who are evaluated based on their credentials, education, experience, and pricing. The best part? - there is no fee to find an advisor.
